Resveratrol for Heart & Circulation

Activated platelets clumping, the first step of a clot
Activated platelets clumping, the first step of a clot

Resveratrol became a household word because of the heart. In the early 1990s the "French paradox" — the observation that the French seemed to have relatively low rates of coronary heart disease despite a diet rich in saturated fat — was popularized on American television and pinned, plausibly but loosely, on red wine and its polyphenols. That single story launched a supplement industry. This page separates what is real from what is folklore: the paradox itself is now widely regarded as largely a statistical artifact; the genuine vascular effects of resveratrol (on the endothelium, blood pressure, platelets, and inflammation) are real but modest, mostly measured on surrogate markers, and mostly demonstrated at supplement doses far beyond anything a glass of wine could ever deliver.


Table of Contents

  1. The Cardiovascular Claim
  2. The French Paradox — Mostly a Myth
  3. Endothelial Function and Nitric Oxide
  4. Blood Pressure
  5. Cholesterol and Lipids
  6. Platelets and Clotting
  7. Inflammation in Coronary Artery Disease
  8. The Dose and Bioavailability Problem
  9. Honest Bottom Line
  10. Cautions and Interactions
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The Cardiovascular Claim

The mechanistic case for resveratrol as a cardiovascular protectant is genuinely attractive on paper. In laboratory models it relaxes blood vessels by increasing nitric oxide, blunts the oxidation of low-density lipoprotein (LDL) cholesterol, discourages platelets from clumping, quiets the inflammatory signaling that drives atherosclerotic plaque, and switches on the same SIRT1 and AMP-activated protein kinase (AMPK) pathways that mediate the cardiovascular benefits of exercise. If all of these translated cleanly into humans at achievable doses, resveratrol would be a remarkable drug.

The reality is more sober. Almost every human cardiovascular trial of resveratrol has measured surrogate endpoints — a number on a machine (flow-mediated dilation, blood pressure, an inflammatory marker) rather than a heart attack prevented or a life extended. Surrogate improvements are encouraging but not the same as clinical benefit; the history of cardiology is littered with drugs that improved a surrogate and then failed to help, or even harmed, when tested on hard outcomes. No trial has ever shown that resveratrol prevents heart attacks, strokes, or cardiovascular death. That is the honest ceiling on everything below.

Back to Table of Contents

The French Paradox — Mostly a Myth

The phrase "French paradox" was popularized after Serge Renaud and Michel de Lorgeril published a 1992 Lancet analysis linking moderate wine consumption to lower coronary heart disease mortality, and after a widely watched 1991 television segment brought the idea to a mass audience. The intuitive story — a compound in red wine protects the French heart — is emotionally satisfying and almost certainly wrong as usually told.

Several later analyses have dismantled the paradox as a genuine biological puzzle:

Even if a modest real effect of moderate wine remains after all corrections, attributing it to resveratrol is a further leap that the evidence does not support. Any cardiovascular benefit of wine is far more plausibly attributed to ethanol's effects on high-density lipoprotein (HDL) and clotting, to the broader polyphenol mix, or to the lifestyle that accompanies moderate drinking — and the resveratrol content of wine (see below) is far too small to be pharmacologically active. The French paradox is best understood as a cautionary tale about turning an epidemiological curiosity into a supplement.

Back to Table of Contents

Endothelial Function and Nitric Oxide

The endothelium — the single-cell lining of blood vessels — controls vascular tone by releasing nitric oxide (NO), a gas that signals the smooth muscle in the vessel wall to relax. Healthy endothelial function is an early casualty of aging, diabetes, and atherosclerosis, and it can be measured non-invasively as flow-mediated dilation (FMD): how much the brachial artery widens after a brief cuff occlusion.

Resveratrol upregulates endothelial nitric oxide synthase (eNOS) in cell and animal models, and several small human trials have reported acute and short-term improvements in flow-mediated dilation after resveratrol, sometimes in a dose-dependent fashion and often more pronounced in people who already have impaired vascular function (obese or diabetic participants). This is one of the more reproducible human signals for resveratrol.

The caveats are the familiar ones: FMD is a surrogate marker, the trials are small and short, and the effect size, while statistically detectable, is modest. Improved FMD is a reasonable hint that resveratrol does something real to the vasculature, but it is not evidence that it prevents cardiovascular events. Pooled trials give a sense of the size. A 2022 meta-analysis of 17 randomised trials (21 trial arms) found that resveratrol raised flow-mediated dilation by 1.43% (95% CI 0.98 to 1.88) and lowered the adhesion marker ICAM-1 by 7.09 ng/ml, with no significant change in VCAM-1, fibrinogen or PAI-1 (Mohammadipoor 2022). A 2021 meta-analysis of red-wine polyphenols, which included 37 human studies, found a small fall in systolic blood pressure overall (−2.6 mmHg), larger in the pure-resveratrol studies (−3.7 mmHg), but no significant effect on diastolic pressure or on flow-mediated dilation (Weaver 2021). For the disease processes this pathway matters in, see our pages on atherosclerosis and coronary artery disease.

Back to Table of Contents

Blood Pressure

Blood pressure is the cardiovascular endpoint where the human resveratrol data are clearest, precisely because it has been meta-analyzed. Liu and colleagues pooled six randomized controlled trials (247 participants) in Clinical Nutrition and reached a nuanced conclusion: across all doses, resveratrol did not significantly lower either systolic or diastolic pressure. In a subgroup analysis, however, higher doses (at or above 150 mg per day) produced a significant reduction in systolic pressure, with no effect on diastolic pressure. In that subgroup systolic pressure fell by 11.90 mmHg (95% CI −20.99 to −2.81, P = 0.01), a wide range drawn from six small trials; lower doses showed no significant effect, and the authors' meta-regression did not find a dose effect on systolic or diastolic pressure.

A 2026 umbrella review that gathered 45 systematic reviews of randomised trials rated four resveratrol effects as backed by high-certainty evidence: lower systolic blood pressure (−7.97 mmHg) and diastolic blood pressure (−3.55 mmHg) in people with type 2 diabetes, a smaller waist circumference (−0.80 cm), and lower total cholesterol in overweight adults (−0.19 mmol/L) (Sun 2026).

The honest reading is that resveratrol has, at best, a small blood-pressure effect that shows up mainly in systolic numbers and, in the Liu analysis, mainly at supplement-level doses. It is not a substitute for established antihypertensive therapy, weight loss, sodium reduction, or exercise, all of which have far larger and better-documented effects. See our hypertension page for the interventions with the strongest evidence.

Back to Table of Contents

Cholesterol and Lipids

Resveratrol's effects on blood lipids are inconsistent. Some trials, particularly in people with existing coronary disease or diabetes, report small reductions in low-density lipoprotein cholesterol, oxidized low-density lipoprotein, or triglycerides; others find no change at all. A grape-extract supplement standardized to resveratrol reduced oxidized low-density lipoprotein and apolipoprotein B in statin-treated patients undergoing primary cardiovascular prevention in one of the Tomé-Carneiro trials. In that triple-blind trial, 75 statin-treated patients took one 350 mg capsule a day for 6 months of a resveratrol-enriched grape extract (8 mg of resveratrol), the same grape extract without resveratrol, or placebo. On the resveratrol extract, LDL cholesterol fell 4.5%, apolipoprotein B 9.8% and oxidized LDL 20%; the extract without resveratrol lowered only LDL cholesterol (by 2.9%), and the placebo group did not change. It is a genuinely interesting result, but one obtained with a whole grape-polyphenol extract rather than pure resveratrol, and in patients already on a statin.

The pattern across the lipid literature is that where resveratrol appears to help, the effect is small, is more likely in already-diseased populations, and is easily swamped by diet and by statin therapy. A 2026 meta-analysis of seven randomised trials found that resveratrol did not change apolipoprotein B (WMD 2.11 mg/dL, 95% CI −1.53 to 5.75, p = 0.26) or apolipoprotein A-I (WMD −1.43 mg/dL, p = 0.46), so the apolipoprotein B fall in the single grape-extract trial was not seen across trials (Simental-Mendía 2026). Pooled trials show at most a small total-cholesterol fall in overweight adults (−0.19 mmol/L in the 2026 umbrella review) and no change in apolipoprotein B or A-I.

Back to Table of Contents

Platelets and Clotting

Part of the original wine-and-heart hypothesis was antiplatelet: resveratrol inhibits platelet aggregation in vitro, reducing the tendency of platelets to clump and initiate a clot on a ruptured plaque. This is mechanistically real in the test tube and in animal models. In humans, the clinical relevance is uncertain, and it cuts both ways — a genuine antiplatelet effect would also mean an increased bleeding tendency, which is the basis for the drug-interaction cautions below. There is no evidence that dietary or supplemental resveratrol produces a clinically meaningful antithrombotic benefit, so there is no evidence on which it could stand in for aspirin or prescribed anticoagulants.

Back to Table of Contents

Inflammation in Coronary Artery Disease

Atherosclerosis is now understood as a chronic inflammatory disease of the arterial wall, not merely passive cholesterol deposition. Resveratrol quiets inflammatory signaling (it inhibits the master inflammatory transcription factor NF-κB and reduces pro-inflammatory cytokines), which makes anti-inflammatory cardiovascular benefit biologically plausible.

The most cited human data come from the Tomé-Carneiro group in Spain, who ran one-year trials of a grape extract containing resveratrol in patients with stable coronary artery disease taking optimal medical therapy. They reported increased serum adiponectin (an anti-inflammatory, insulin-sensitizing hormone) and downregulation of pro-inflammatory genes and microRNAs in circulating immune cells. The one-year trial cited on this page enrolled men with type 2 diabetes and high blood pressure who had coronary artery disease, and gave a grape extract containing 8 mg of resveratrol a day; serum inflammatory markers did not change except for falls in IL-6 and ALP, and body weight, blood pressure, glucose, HbA1c and lipids were not affected beyond what the men's usual medication achieved. These are among the most encouraging cardiovascular results in the literature — but they come with limits: the trials were small, used a grape-polyphenol extract rather than isolated resveratrol, came largely from a single research group, and again measured inflammatory surrogates rather than clinical events.

A 2024 meta-analysis of 10 randomised trials in coronary artery disease found that resveratrol lowered TNF-alpha in primary-prevention studies (people at risk of coronary disease), but IL-6 did not change significantly (P=0.58 for primary and P=0.57 for secondary prevention), and secondary-prevention studies in people with confirmed coronary disease showed no significant results (Damay 2024).

Back to Table of Contents

The Dose and Bioavailability Problem

The positive cardiovascular results above raise a question about dose, and the trials do not line up neatly. In the Liu 2015 blood-pressure meta-analysis, only the subgroup taking 150 mg a day or more showed a significant fall in systolic pressure, yet its meta-regression “did not indicate dose effects of resveratrol” on systolic or diastolic pressure. The Tomé-Carneiro trials, among the most positive results on this page, used a grape extract containing 8 mg of resveratrol a day. A 2024 review of vascular trials found “contrasting results on the effects of resveratrol supplementation and vascular biomarkers without dose-dependent effect”: studies that gave resveratrol through red wine reported significant effects although their resveratrol content was much lower than tablet doses, “while other studies with often extreme resveratrol supplementation resulted in null findings” (Godos 2024). Red wine contains only about 0.1 to 2 milligrams of trans-resveratrol per liter — so a typical 150 mL glass supplies on the order of a few tenths of a milligram, far below the 150 mg-a-day supplement doses. To reach that level from wine alone, a person would have to drink a physically impossible (and lethally alcoholic) volume. Whether resveratrol itself explains the effects seen with wine and low-dose grape extracts is not settled, since wine also delivers alcohol and many other polyphenols.

Compounding this, resveratrol taken by mouth is extensively converted to glucuronide and sulfate metabolites during first-pass metabolism, so the amount of free, active resveratrol circulating in the blood is very low even after a large supplement dose. This is the central reason the human cardiovascular effects are so much more modest than the cell-culture experiments predicted. See the Antioxidant & Cellular Protection page for the full pharmacokinetic story.

Back to Table of Contents

Honest Bottom Line

Back to Table of Contents

Cautions and Interactions

Back to Table of Contents

Key Research Papers

  1. Renaud S, de Lorgeril M (1992). Wine, alcohol, platelets, and the French paradox for coronary heart disease. The Lancet, 339(8808), 1523–1526. — PubMed PMID: 1351198
  2. Liu Y, Ma W, Zhang P, He S, Huang D (2015). Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clinical Nutrition, 34(1), 27–34. — PubMed PMID: 24731650
  3. Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al. (2012). Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Molecular Nutrition & Food Research, 56(5), 810–821. — PubMed PMID: 22648627
  4. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al. (2013). One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacological Research, 72, 69–82. — PubMed PMID: 23557933
  5. Baur JA, Sinclair DA, et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444(7117), 337–342. — PubMed PMID: 17086191
  6. Walle T, et al. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition, 32(12), 1377–1382. — PubMed PMID: 15333514
  7. Law M, Wald N (1999). Why heart disease mortality is low in France: the time lag explanation. BMJ, 318(7196), 1471–1476. — PubMed PMID: 10346778
  8. Godos J, Romano GL, Gozzo L, et al. (2024). Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiota. Frontiers in Pharmacology, 15, 1368949. — PubMed PMID: 38562461
  9. Sun JN, Yang R, Fang L, et al. (2026). Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutrition Journal, 25(1), 63. — PubMed PMID: 41987155
  10. Simental-Mendía LE, Arce-Quiñones M, Sahebkar A (2026). No beneficial effect of resveratrol supplementation on plasma apolipoprotein B and apolipoprotein A-I levels: a systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 104866. — PubMed PMID: 42471257
  11. Mohammadipoor N, Shafiee F, Rostami A, et al. (2022). Resveratrol supplementation efficiently improves endothelial health: a systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research, 36(9), 3529–3539. — PubMed PMID: 35833325
  12. Weaver SR, Rendeiro C, McGettrick HM, Philp A, Lucas SJE (2021). Fine wine or sour grapes? A systematic review and meta-analysis of the impact of red wine polyphenols on vascular health. European Journal of Nutrition, 60(1), 1–28. — PubMed PMID: 32303823
  13. Damay VA, Ivan I (2024). Resveratrol as an anti-inflammatory agent in coronary artery disease: a systematic review, meta-analysis and meta-regression. Chinese Journal of Integrative Medicine, 30(10), 927–937. — PubMed PMID: 38958883

PubMed Topic Searches

  1. PubMed: resveratrol & endothelial function
  2. PubMed: French paradox critiques
  3. PubMed: resveratrol & platelets
  4. PubMed: resveratrol & atherosclerosis
  5. PubMed: resveratrol & nitric oxide

Back to Table of Contents

Connections

Back to Table of Contents